Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Response Assessment to Pembrolizumab With Standard of Care Therapy in Oligometastatic Brain Tumors From Melanoma, and Glioblastoma Using Ferumoxytol Steady State Imaging? A Pilot Study

Trial Profile

Response Assessment to Pembrolizumab With Standard of Care Therapy in Oligometastatic Brain Tumors From Melanoma, and Glioblastoma Using Ferumoxytol Steady State Imaging? A Pilot Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Ferumoxytol (Primary) ; Pembrolizumab
  • Indications Brain cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 14 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 20 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top